SmartPeptide
Start Free
Fat LossStrong human clinical evidence FDA-approved label on file

Tirzepatide

Dual GIP / GLP-1 receptor agonist with strong Phase 3 evidence in type 2 diabetes (SURPASS) and obesity (SURMOUNT).

Educational only — not medical advice. SmartPeptide does not prescribe, diagnose, or treat. Always consult a licensed healthcare provider before using any peptide, supplement, medication, or protocol.

What the research shows

SURMOUNT-1 (n=2,539) showed up to ~22.5% body-weight reduction at 72 weeks at the 15 mg dose. SURPASS trials demonstrated robust HbA1c improvement vs comparators in type 2 diabetes.

What's still experimental

Direct head-to-head with semaglutide for cardiovascular outcomes is still maturing. Long-term durability of weight loss after discontinuation remains under study.

Anecdotal / community reports

Rapid weight-loss anecdotes are common; many ignore baseline lifestyle changes and gradual dose escalation that the trials used.

Anecdotal reports are NOT scientific evidence. They reflect personal experience and may not generalize.

FDA approval status

Source: openFDA + DailyMed (NIH/NLM)
2 FDA-approved labels on file
  • Zepbound
    (TIRZEPATIDE) · Eli Lilly and Company
    Full label on DailyMed
    Indications & usage

    1 INDICATIONS AND USAGE ZEPBOUND ® is indicated in combination with a reduced-calorie diet and increased physical activity: to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition. to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity. ZEPBOUND is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist indicated in combination with a reduced-calorie diet and increased physical activity: to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition. ( 1 ) to tr…

    Dosage & administration

    2 DOSAGE AND ADMINISTRATION Recommended Dose Escalation Schedule The recommended starting dosage is 2.5 mg injected subcutaneously once weekly for 4 weeks. Increase the dosage in 2.5 mg increments after at least 4 weeks until recommended maintenance dosage is achieved. ( 2.1 ) Consider treatment response and tolerability when selecting the maintenance dosage. ( 2.1 ) Recommended Maintenance and Maximum Dosage Weight Reduction and Long-Term Maintenance: 5 mg, 10 mg, or 15 mg injected subcutaneously once weekly. ( 2.2 ) Obstructive Sleep Apnea: 10 mg or 15 mg injected subcutaneously once weekly. ( 2.2 ) Maximum Recommended Dosage: 15 mg injected subcutaneously once weekly. ( 2.2 ) Administration Instructions Refer to the Full Prescribing Information for additional important administration in…

    Warnings

    5 WARNINGS AND PRECAUTIONS Severe Gastrointestinal Adverse Reactions: Use has been associated with gastrointestinal adverse reactions, sometimes severe. ZEPBOUND is not recommended in patients with severe gastroparesis. ( 5.2 ) Acute Kidney Injury Due to Volume Depletion: Monitor renal function in patients reporting adverse reactions that could lead to volume depletion. ( 5.3 ) Acute Gallbladder Disease: Has been reported in clinical trials. If cholecystitis is suspected, gallbladder studies and clinical follow-up are indicated. ( 5.4 ) Acute Pancreatitis: Has been observed in patients treated with GLP-1 receptor agonists, or ZEPBOUND. Discontinue if pancreatitis is suspected. ( 5.5 ) Hypersensitivity Reactions: Serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) have been r…

  • Mounjaro
    (TIRZEPATIDE) · Eli Lilly and Company
    Full label on DailyMed
    Indications & usage

    1 INDICATIONS AND USAGE MOUNJARO ® is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. MOUNJARO ® is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. ( 1 )

    Dosage & administration

    2 DOSAGE AND ADMINISTRATION The recommended starting dosage is 2.5 mg injected subcutaneously once weekly. ( 2.1 ) After 4 weeks, increase to 5 mg injected subcutaneously once weekly. ( 2.1 ) If additional glycemic control is needed, increase the dosage in 2.5 mg increments after at least 4 weeks on the current dose. ( 2.1 ) Maximum dosage ( 2.1 ): Adults: 15 mg subcutaneously once weekly. Pediatric patients 10 years of age and older: 10 mg subcutaneously once weekly. Administer once weekly at any time of day, with or without meals. ( 2.2 ) Inject subcutaneously in the abdomen, thigh, or another person should inject in the back of the upper arm. Rotate injection sites with each dose. ( 2.2 ) Refer to the Full Prescribing Information for additional important administration instructions abou…

    Warnings

    5 WARNINGS AND PRECAUTIONS Acute Pancreatitis: Has been observed in patients treated with GLP-1 receptor agonists, or MOUNJARO. Discontinue if pancreatitis is suspected. ( 5.2 ) Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin: Concomitant use with an insulin secretagogue or insulin may increase the risk of hypoglycemia, including severe hypoglycemia. Reducing dose of insulin secretagogue or insulin may be necessary. ( 5.3 ) Hypersensitivity Reactions: Serious hypersensitivity reactions (e.g., anaphylaxis and angioedema) have been reported. Discontinue MOUNJARO if suspected and promptly seek medical advice. ( 5.4 ) Acute Kidney Injury Due to Volume Depletion: Monitor renal function in patients reporting adverse reactions that could lead to volume depletion. ( 5.5 ) Sev…

Doses studied in research

Source: FDA-approved label

What published trials tested or FDA-approved labels specify. Reporting research facts — not a SmartPeptide recommendation.

FDA-approved labelMounjaro / Zepbound FDA labels (DailyMed)
Indication studied: Type 2 diabetes (Mounjaro) and chronic weight management (Zepbound)
Starting
2.5mg(2,500 µg)
once weekly · subcutaneous

Weeks 1-4

Open calculator
Typical
10mg(10,000 µg)
once weekly · subcutaneous

Common maintenance

Open calculator
Maximum
15mg(15,000 µg)
once weekly · subcutaneous

Top dose tested + approved

Open calculator

Notes from the source: Titration: 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg, increasing every 4 weeks based on tolerability.

Important framing: The numbers above are what published trials tested or what FDA-approved labels specify. They are NOT a SmartPeptide recommendation for you. Trial doses come paired with screening, monitoring, and clinician oversight. Always consult a licensed clinician before any peptide use.

FDA enforcement & recalls

Live · openFDA Drug Enforcement API
Total actions
21
recalls + withdrawals
Ongoing
21
not yet completed
Class I (serious)
1
health hazard / death risk
  • Class IIOngoing· Voluntary: Firm initiated
    FDA record

    Tirzepatide Inj, 15mg x 4, Sterile Multi-Dose Vial, Rx only, Nomida, 25055 W Valley Pkwy, Suite 106, Olathe, KS 66061, NDC 84223-002-04.

    Reason: Lack of Assurance of Sterility

    Feb 26, 2026·New Life Pharma LLC
  • Class IIOngoing· Voluntary: Firm initiated
    FDA record

    Tirzepatide Inj, 10mg, Sterile Multi-Dose Vial, Rx only, Nomida, 25055 W Valley Pkwy, Suite 106, Olathe, KS 66061, NDC 84223-002-03.

    Reason: Lack of Assurance of Sterility

    Feb 26, 2026·New Life Pharma LLC
  • Class IIOngoing· Voluntary: Firm initiated
    FDA record

    Tirzepatide Injection, 27 mg/3 mL (9 mg/mL), 3mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd by: ProRx, 619 Jeffers Cir, Exton, PA 19341. NDC: 84139-209-03

    Reason: Lack of Assurance of Sterility

    Oct 15, 2025·ProRx LLC
  • Class IIOngoing· Voluntary: Firm initiated
    FDA record

    Tirzepatide, 60mg/10 mL for Injection, 10mL vial lyophilized, all presentations, GenoGenix, LLC, 2840 NW 2nd Ave Ste 204 Boca Raton, FL 33431-6692. Also labeled as manufactured for Extension Health an…

    Reason: Lack of Assurance of Sterility

    Jul 30, 2025·GenoGenix LLC
  • Class IIOngoing· Voluntary: Firm initiated
    FDA record

    Tirzepatide + Niacinamide 4.4 mg + 1.0mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, 2 mL Multi Dose Vial, Refrigerate, Do not freeze, Aequita Pharmacy LLC, Kirkland,…

    Reason: Lack of Processing Controls.

    Jul 18, 2025·AEQUITA PHARMACY
Showing 8 of 21 total enforcement actions. See full FDA history →
FDA classifications: Class I = reasonable probability of serious adverse health consequences or death. Class II = temporary or medically reversible adverse consequences. Class III = unlikely to cause adverse health consequences.

Mechanism & targets

ChEMBL · UniProt · Open Targets

Molecule (ChEMBL)

View on ChEMBL
Known mechanisms of action
  • CHEMBL4383
    agonistGastric inhibitory polypeptide receptor agonist
  • CHEMBL1784
    agonistGlucagon-like peptide 1 receptor agonist

Protein targets (UniProt)

  • Gastric inhibitory polypeptide receptor
    P48546gene: GIPRHomo sapiens· 466 aaReviewed

    This is a receptor for GIP. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase

  • Glucagon-like peptide 1 receptor
    P43220gene: GLP1RHomo sapiens· 463 aaReviewed

    G protein-coupled receptor for glucagon-like peptide 1 (GLP-1) (PubMed:19861722, PubMed:26308095, PubMed:27196125, PubMed:28514449, PubMed:7517895, PubMed:8216285, PubMed:8405712). Ligand binding triggers activation of a signaling cascade that leads to the activation of adenylyl cyclase and increased intracellular cAMP levels (PubMed:19861722, PubMed:26308095, PubMed:27196125, PubMed:28514449, PubMed:7517895, PubMed:8216285, PubMed:8405712). Plays a role in regulating insulin secretion in respon…

  • Albumin
    P02768gene: ALBHomo sapiens· 609 aaReviewed

    Binds water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs (Probable). Its main function is the regulation of the colloidal osmotic pressure of blood (Probable). Major zinc transporter in plasma, typically binds about 80% of all plasma zinc (PubMed:19021548). Major calcium and magnesium transporter in plasma, binds approximately 45% of circulating calcium and magnesium in plasma (By similarity). Potentially has more than two calcium-binding sites and might additionally bind cal…

Live research

PubMed · ClinicalTrials.gov · Europe PMC · OpenAlex
PubMed papers
2,248
total
Human studies
0
MeSH: humans
Clinical trials
0
published
Active trials
95
273 total registered

Clinical trials (ClinicalTrials.gov)

All trials for "tirzepatide"

Europe PMC — 6,299 additional records

Includes EU/UK studies and PubMed Central full-text articles. Often surfaces research weeks before PubMed indexes it.

Research volume (OpenAlex topic graph)

Total works
12,483
all years
Last 5 years
12,332
recent activity
Open access
9,818
freely readable
OA share
79%
of all works

Human clinical evidence

Semantic Scholar · AI TLDRs · influence-ranked
Total indexed
3,482
all human + lab studies
Meta-analyses
0
highest evidence
Systematic reviews
1
quality-weighted
Clinical trials
1
published RCTs etc.

Most influential human studies

Ranking blends meta-analysis > systematic review > clinical trial weight with influential-citation count and recency. AI TLDRs by Semantic Scholar / Allen Institute for AI.

Research funding & verification

NIH RePORTER · CrossRef DOI registry

NIH-funded research

U.S. National Institutes of Health
Funded projects
40
all years
Top award sum
$21.3M
aggregate USD
Years covered
4
research span
Largest active / recent grants

Publication landscape

CrossRef · DOI registry
Indexed works (CrossRef)
3,223
all DOIs registered
Retracted papers
0
no retractions on record
Top funders of indexed research
  • Eli Lilly and Company183 works
  • National Natural Science Foundation of China25 works
  • National Institutes of Health14 works
  • Eli Lilly Japan9 works
  • Mitsubishi Tanabe Pharma Corporation8 works
  • National Institute of Diabetes and Digestive and Kidney Diseases7 works

Funder diversity is a credibility signal. Research concentrated in a single drug company's funding warrants more scrutiny than research funded across NIH, charities, and academic grants.

Preprints — cutting edge

bioRxiv · medRxiv · via Europe PMC

Preprints have NOT been peer-reviewed. They are early research shared by authors before formal validation. Treat findings as preliminary.

Showing 6 of 166 preprints indexed by Europe PMC.

Known risks

Similar profile to GLP-1 agonists. Prescription-only.

Reported side effects

GI side effects, injection-site reactions.

FDA adverse event reports (FAERS)

Updated quarterly by FDA
Reports filed
140,520
FAERS, all years
Serious reports
24,013
17% of reports
Top reporting countries
  • US123,962
  • GB7,111
  • JP966
  • EU940

Most-reported reactions

  • Incorrect Dose Administered
    28,117
  • Nausea
    14,302
  • Injection Site Pain
    13,184
  • Extra Dose Administered
    9,000
  • Diarrhoea
    8,315
  • Off Label Use
    8,291
  • Vomiting
    6,904
  • Drug Ineffective
    5,419
  • Constipation
    5,252
  • Injection Site Haemorrhage
    5,035

Counts from FDA Adverse Event Reporting System (FAERS). Voluntary reports — they show what was reported, not whether the drug caused the event. Many reports lack confirmation. FAERS docs

What requires medical supervision

Prescription medication with the same MTC/MEN-2 contraindications and similar GI/gallbladder safety considerations as GLP-1 monoagonists.

Questions for your clinician

  • Is tirzepatide more appropriate than semaglutide for me, and why?
  • What injection-site rotation and titration plan do you recommend?
  • What labs should we follow?

Editorially curated references

Discussions about Tirzepatide

Start a discussion
See all Tirzepatide discussions Native, moderated, no buying or selling